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Introduction
Functional diversity of the proteome is mainly achieved by post-translational modifications. One of the most common modifications is glycosylation, which affects protein structure and function. A well suited glycoprotein model is immunoglobulin G (IgG), the most abundant immunoglobulin circulating in blood [1] , as its functional importance and physiological significance has previously been described [1, 2] . Two identical heavy and light chains, respectively, form the IgG polypeptide backbone [3] . The hinge region connecting the antigen-binding part (Fab) with the crystallizable region (Fc) part of IgG is the most variable component and mainly differentiates the IgG subclasses (IgG1, IgG2, IgG3 and IgG4) [3] .
All IgG molecules contain a conserved N-glycosylation site on the Fc portion that controls pro-and anti-inflammatory functions of the glycoprotein [4, 5] . Additionally, about 15 to 25% of IgG molecules contain N-linked glycans in the Fab domain with several functions of their own [6] . The composition of the attached glycans is itself influenced by several factors, such as enzymes and the availability of precursors. N-glycan remodeling happens in the Golgi and the endoplasmic reticulum (ER) [7] and underlies the interaction of donor molecules, co-factors and enzymes including glycosyltransferases and glycosidases [8] .
The complex interaction needed to compose the final functional glycan structure therefore cannot be encoded by a single gene or a combination of genes [8] . Still, the outcome of the enzymatic activities is well regulated and several genes encoding glycosyltransferases have been shown to associate with differing IgG glycosylation patterns [9] .
While genetic regulation of the glycosylation synthesis could be partially elucidated [10, 11] , the impact of epigenetics on IgG glycosylation is still not sufficiently studied. However, it is widely accepted and supported by different studies that the environment and, consequently, epigenetics plays an important role for the N-glycome [8, [12] [13] [14] [15] . Additionally, it has been reviewed in [14] and [15] that epigenetic mechanisms have a key function in the IgG glycosylation pathway.
DNA methylation is one of the best studied epigenetic regulations leading to differential gene expression [16] [17] [18] , especially gene silencing due to heavy methylation [19, 20] 
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A C C E P T E D M A N U S C R I P T With this study we hope to elucidate the role of epigenetics in the entangled pathway leading to definite regulatory IgG glycan compositions. Figure 1 summarizes the initial analysis steps as well as the additional mediation analysis. In total, 3,200 samples were available for our analyses. We studied two different methods of IgG glycosylation, UPLC (left/blue side in Figure 1 ) and LC/MS (right/green side in Figure 1 ). UPLC data was available in TwinsUK (UK adult twin registry; n = 877) [33] and EGCUT (Estonian Genome Center, University of Tartu; n = 148) [34] , while LC/MS was available in KORA F4 (Cooperative Health
Methods
Research in the Augsburg Region; n = 1,630) [35] and LLS (Leiden Longevity Study; n = 619) [36] . The overlapping results from both IgG glycan panels are presented in the middle of Figure 1 and are followed by the results from the additional mediation analysis.
Study Cohorts
General Characteristics on the four cohorts are summarized in table S1.
Cooperative Health Research in the Augsburg Region (KORA F4)
The KORA F4 study, conducted in 2006-2008, is an independent population-based health survey [35] .
The study followed the recommendations of the Declaration of Helsinki and was approved by the local ethical committees.
Information on sociodemographic variables including sex, age, BMI (in kg/m²) was collected by trained medical staff during a standardized interview. White blood cell count (WBC) was measured
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A C C E P T E D M A N U S C R I P T from whole blood plasma and estimated white blood cell proportions were obtained using the method by Houseman et al. [37] . By definition the cell proportions sum up to one, so we excluded from the analysis the least common cell type (NK) with the lowest mean to avoid confounding.
In KORA F4, a total of 3,080 persons participated of whom 1,630 have both DNA methylation and IgG glycopeptides measured. For the mediation analysis in KORA F4, we had 1,594 samples with known smoking status including 671 non-smokers and 923 ever smokers (691 former smokers and 232 current smokers).
Leiden Longevity Study (LLS)
The study protocol of LLS was approved by the local medical ethical committee and the study was conducted according to the recommendations of the Declaration of Helsinki. Written informed consent was obtained from all study participants. LLS collected data on long-lived individuals, their offspring and the partners of the offspring, as controls [36] . For this current study offspring and controls persons have been analyzed (n=619, mean age 59.2 years (range 39-81 years)) with both DNA methylation and IgG glycosylation data available [38] .
UK adult twin registry (TwinsUK)
The TwinsUK cohort includes more than 13,000 monozygotic and dizygotic twin volunteers from all regions across the United Kingdom. Volunteers were not recruited on the basis of any specific trait or disease and have been shown to have diseases and lifestyle characteristics similar to the general population [33, 39] cohort. DNA methylation was measured for 877 randomly selected individuals, from which 609 had information on glycan measurements. White blood cell proportions were estimated using the method by Houseman et al. [37] .
Estonian Genome Center, University of Tartu (EGCUT)
The Estonian Genome Center at the University of Tartu (EGCUT) [34] is a population based biobank which comprises health, genealogical and 'omics' data of close to 52,000 individuals ≥ 18 years of age, closely reflecting the age distribution in the adult Estonian population [34] . The collection of blood samples and the data is conducted according to the Estonian Human Gene Research Act and all participants have signed a broad informed consent.
Participants of the EGCUT have been recruited by clinicians at their offices or data collectors at recruitment offices of the EGCUT. A computer assisted personal interview was completed for each participant, including personal data (place of birth, place(s) of living, nationality etc.), genealogical data (family history, three generations), educational and occupational history and lifestyle data (physical activity, dietary habits, smoking, alcohol consumption, quality of life).
A C C E P T E D M A N U S C R I P T
A blood sample was drawn from each participant during the recruitment. Estimated white blood cell proportions were obtained using the method by Houseman et al. [37] .
In total, 148 individuals have both DNA methylation and IgG glycan measurements. They were selected from a subgroup of "healthy" individuals who have been re-contacted for a second timepoint interview, a subgroup of individuals that died of cancer within five years since recruitment ("healthy" at baseline), and a subgroup of men diagnosed with prostate cancer within five years since recruitment ("healthy" at baseline). Of them, 45 are current, 39 former and 64 never-smokers.
DNA isolation and preparation
A blood sample was drawn from each participant during the recruitment and DNA was isolated using standard procedures. DNA methylation was analyzed with the Illumina HumanMethylation450K
BeadChip [40] . Preceding treatment of the blood samples followed the manufacturer's guidelines.
DNA methylation data were measured with the Illumina HumanMethylation450K BeadChip [40] in all four cohorts.
DNA Methylation Preprocessing
Methylation data from all studies underwent specific initial quality control. Beta-values of DNA methylation as well as appropriate technical covariates were included in the statistical models.
Family structure was accounted for if needed.
For KORA F4, processing of the raw DNA methylation data and initial quality control was accomplished as described in detail in [21] . Following, data from KORA F4 and EGCUT followed the quantile normalization pipeline described by Lehne et al [41] . Data from TwinsUK underwent an initial quality control including e.g. a detection p-value > 0.05 and the exclusion of DNA methylation probes that mapped incorrectly or to multiple locations. Following, the data were beta-mixture quantile normalized as described in [42] .
For LLS, the generation of genome-wide DNA methylation data is described by Bonder et al [43] . The original idat files were generated by the Illumina iScan BeadChip scanner. Subsequently, sample
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quality control was performed using MethylAid [44] . Similar to the pipeline used for the other cohorts, probes with a high detection p-value (> 0.01), probes with a low bead count (< 3 beads), and probes with a low success rate (missings in > 95 %) were excluded from the analysis. Subsequently, imputation was performed to impute the missing values. Functional normalization, as implemented in the minfi package, was used.
Measurement of IgG Glycosylation
The two different methods applied, UPLC and LC/MS as well as the single process steps applied have been described in detail in [9, 11, [45] [46] [47] . In short, for both analytical methods, IgG was first isolated from plasma as presented in [9] .
For KORA F4 and LLS, glycosylation patterns were examined by the analysis of tryptic glycopeptides using the nanoLC-ESI-MS (denoted as LC/MS) method as outlined in [46] subclass. More details on the analytical method can be found in [47] . In total, 20 glycoforms could be observed for both IgG1 and IgG2/3, and 10 peaks describing fucoslyated glycoforms for IgG4.
Glycan profiles for TwinsUK and EGCUT, were investigated by UPLC after IgG isolation and IgG Nglycan release and labeling. Details are provided in [9, 45, 47] . In total, 24 glycan peaks can be distinguished by this approach. For TwinsUK however, the peaks of GP20 and GP21 (see table S2a for details) were not uniquely distinguishable and both traits are excluded in the downstream analysis.
Summarizing, LC/MS measurements provide data on the glycan structure attached to the Fc part of IgG glycopeptides. UPLC data in contrast contain information on the total released IgG glycans from both Fab and Fc parts.
IgG Glycan Preprocessing
Both UPLC and LC/MS measured IgG N-glycans were total area normalized as implemented in the Rpackage 'glycanr' v0.3.0 [49]. We consider glycan percentages for UPLC and glycan percentages per subclass for LC/MS data. Normalization was followed by log-transformation and batch correction (per subclass for LC/MS data) using the ComBat algorithm [50] of the R package 'sva' v3.14.0 [51] . In order to recapture the initial scale, the data were exponentiated and then derived traits were calculated as provided by the glycanr-package [49] and as in [45] . See the tables S2a and S2b for an overview of initial and derived traits for both UPLC and LC/MS data. To ensure normal distribution of ACCEPTED MANUSCRIPT
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the phenotypes, data were inverse normal rank transformed [52] . For similar derived traits however, the normal rank transformation led to the exactly same values for differing traits (e.g. LC_IGP42 and LC_IGP44; LC_IGP43 and LC_IGP45 in the KORA F4 cohort). We kept those similar traits and flagged them within each cohort separately.
Statistical Methods
Primary EWAS analysis
In each cohort we performed linear regression models for all glycan traits with each glycan as 
Meta-analysis
For UPLC and LC/MS data respectively, we performed a random effects meta-analysis using the package 'metafor' [56] from the statistical software R (Version 3.2.1). Inverse variance weighting and the restricted maximum likelihood estimator were used for the analysis.
We excluded six glycan traits (LC_IGP170, LC_IGP148, LC_IGP147, LC_IGP149, LC_IGP107, LC_IGP150)
in the LC/MS dataset due to their deviating QQplots (an example is shown in supplemental figure 1)
in the meta-analysis in order to reduce bias from measurement errors. Additionally, these traits showed an uncommonly large number of associations (> 5,000) randomly across the genome.
We set the Bonferroni- 
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Mediation analysis
CpG-sites and their associated IgG glycans remaining after the exclusion criteria were further used in a mediation analysis with respect to smoking. We performed Sobel tests [58, 59] to assess the mediation effect and performed an analysis of variance for the appropriate CpG -glycan combinations. All analyses were conducted in R by using the package 'bda' v5. combinations), respectively (see Table 2a and 2b for additional information on the selected combinations).
Results
Figure 1 displays the analysis workflow for the identification of associations between CpG-sites and
IgG glycosylation traits.
For the UPLC meta-analysis, we found in total 124 associations between 27 glycan traits and 26 CpGsites to be at least suggestively significant at Bonferroni-correction (p < 1.1 x 10 -7
, Bonferronicorrected for number of CpG-sites). Out of these associations, 61 were epigenome-wide significant ) for one glycan panel and have at least one association with p < 0.001 in the other glycan panel.
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Of the 7 CpG sites ( Figure 1 , For the UPLC IgG traits, 20 IgG glycan traits exhibit similar association to the CpG-sites and they mostly represent the percentage of fucosylation with and without bisecting GlcNAc, as well as the ratio between structures containing a bisecting GlcNAc and lacking a bisecting GlcNAc.
The associated IgG glycans in the LC/MS panel are 2 derived traits, LC_IGP43 and LC_IGP45, which can be described them as the relation of fucosylated monosialylated structures with bisecting GlcNAc to all fucosylated and monosialyated structures within IgG1.
In general, a decrease of DNA methylation at the CpG-sites on chromosome 1, 2, 5 and 19 is associated with an increase of structures with bisecting GlcNAc compared to structures without bisecting GlcNAc.
Mediation Analysis
Since the methylation at all 7 CpG-sites associating significantly with IgG glycosylation traits ( Figure 1 (table T2a) .
A summarizing plot of the mediation analysis is given in Figure 2 . These results hint at a possible mediating effect of DNA methylation on the relation between smoking and IgG glycosylation.
Discussion
In the current paper, we aimed at identifying methylation levels of CpG-sites to be associated with IgG glycosylation traits. We conducted meta-analyses for UPLC IgG glycan data (n = 757) and LC/MS IgG glycan data (n = 2,249) using data from four cohorts (LLS, KORA F4, EGCUT, TwinsUK) and around 3,000 samples contributing to our study. We found 7 CpG-sites associating with IgG glycosylation traits. Out of these, 6 CpG-sites on chromosome 1, 2, 5, and 19 are associated with an increase of structures with bisecting GlcNAc compared to structures without bisecting GlcNAc (UPLC data).
Additionally, we found 3 CpG-sites on chromosome 2 and 6 of which a decrease in DNA methylation is associated with an increase of IgG1 fucosylated monosialylated structures with bisecting GlcNAc compared to all fucosylated and monosialylated IgG1 structures (LC/MS data). Two CpG-sites on chromosome 2, cg05951221 and cg21566642, associate with both UPLC as LC/MS IgG glycan traits.
that are suggestive (p < 1.1 x 10 -7
) in at least one panel (table T1 ) and show associations with p < 0.001 in the other. Out of these, 2 CpG-sites reached the significance threshold of 10 -7 in both panels.
In depth mediation analysis revealed that the effect of smoking on IgG glycosylation levels is mediated by the identified 7 CpG-sites on chromosome 1, 2, 5, 6, and 19.
In fact, all 7 CpG-sites on chromosome 1 (GNG12), chromosome 2 (ALPPL2), chromosome 5 (AHRR), Additionally, smoking has been associated with increased branching of glycan structures [29] .
Through the mediation analysis for all 7 CpG-sites, we can hypothesize that smoking leads to a higher ratio between IgG glycan structures with bisecting GlcNAs compared to structures without bisecting GlcNAs, i.e. an increased branching of IgG glycopeptides, via a decrease of DNA methylation at these CpG-sites. For the LC/MS data, we can specify the structure to be additionally fucosylated and monosialylated. None of the loci has been associated to IgG glycosylation before, especially not in a hypothesis-free genome-wide analysis. The effect of these CpG-sites thus may have a specific role in the interaction of smoking and IgG glycosylation [11] .
On chromosome 1, the CpG-site cg25189904 is located within the region of GNG12-AS1, a GNG12
antisense RNA 1. Its antisense orientation to the gene DIRAS3 causes the transcriptional silencing of 
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confirms that, at least for two CpG-sites, the effect of smoking on IgG glycosylation, is mediated by DNA methylation. We therefore recommend further studies in order to unfold the interaction of the three components. A C C E P T E D M A N U S C R I P T A C C E P T E D M A N U S C R I P T A C C E P T E D M A N U S C R I P T 
List of Tables
